Model for assessment of Cystatin C as predictive cardiovascular risk marker in patients with Chronic Kidney Disease

  • Manoj Kumar
  • Asgar Ali Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India.
  • Reema Sharma
  • Raj Narayan Gupta
  • Alok Ranjan
  • Kishan Kumar Sharma
  • Rathish Nair
  • Sadhana Sharma Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India.
Keywords: Cystatin C, Creatinine, Chronic Kidney Disease, Cardiovascular disease, Diabetes, HDL, LDL, VLDL


Background: Cystatin C, a protease inhibitor synthesized in all nucleated cells, has been proposed as a replacement for serum creatinine for the assessment of renal function, particularly to detect small reductions in glomerular filtration rate. In this study we determine a novel model to access cystatin C level of patients having cardiovascular risks with chronic kidney disease if other parameters are known.Methods: Blood samples were collected (total 397 subjects) from patients with chronic kidney disease (CKD), cardio vascular disease (CVD) and both CKD with CVD, along with the normal healthy controls. Lipid profile, urea, creatinine, hs-CRP, physiological parameters and cystatin C were analyzed.Result: We found that proportion of diabetics were significantly higher among diseased persons as compared to control subjects (Chi-square=53.61; p=0.0001). Mean values of total cholesterol, triglyceride, VLDL, urea, creatinine and cystatin C among CKD group as well as in CVD group of patients were significantly higher (p<0.05), while total protein, albumin and haemoglobin were significantly lower (p<0.05) as compared to healthy controls. In CKD patients with CVD, the mean values of potassium, glucose, urea, creatinine, cystatin C and total leucocyte count  were significantly higher (p<0.05), while total protein, albumin and hemoglobin were significantly lower (p<0.05) as compared to healthy controls.Conclusion: This study has demonstrated a novel predictive model which is cost ineffective than the gold standard for the assessment of serum cystatin C is an endogenous risk marker in the patients of cardiovascular with Chronic Kidney Disease if other parameters.


1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.
2. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives; a position statement from Kidney Disease Improving Global Outcomes. Kidney Int. 2007;72:247–259.
3. Ninomiya T, Kiyohara Y, Doi Y, Arima H , Harada A, et al. Impact of kidney disease and blood pressure on the development of cardiovascular disease:an overview from the japan Arte-riosclerosis Longitudinal Study. Circulation. 2008;118:2694-2701.
4. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol. 2002;57:327-35.
5. Grubb A, Löfberg H. Human γ-trace, a basic microprotein: amino acid sequence and presence in the adenohypophysis. Proc Natl Acad Sci USA. 1982;79:3024-7.
6. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci 2004;41:467-50.
7. Tanaka A, Suemaru K, Araki H. A new approach for evaluating renal function and its practical application. J Pharmacol Sci. 2007;105:1–5.
8. Grubb A. Diagnostic value of analysis of Cystatin C and protein HC in biological fluids. Clin Nephrol. 1992;38:20-27.
9. Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum Cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–21.
10. Macdonald J, Marcora S, Jibani M, et al. GFR estimation using Cystatin C is not independent of body composition. Am J Kidney Dis. 2006;48:712–719.
11. Stevens LA, Schmid CH, Greene T, et al. Factors other than glomerular filtration rate affect serum Cystatin C levels. Kidney Int. 2009;75:652–660.
12. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
13. Shlipak MG, Katz R, Sarnak MJ et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006;145:237–246.
14. Jaffe M. Ueber den Niederschlag, welchen Pikrinsäure im normalen Harn erzeugt und über eine neue Reaction des Kreatinins. Zeitschrift fur Physiologische Chemie. 1886;10:391–400.
15. Esteban-salan M, Guimon-Bardesi A, et al. Analytical and clinical evaluation of two homogeneous assays for LDL–Cholesterol in hyperlipidemic patient. Clin Chem. 2000;46:1121-1131.
16. Weichselbaum TE. An accurate and rapid method for the determination of protein in small amount of blood serum and plasma. Amer J Clin Path. 1946;10:40-49.
17. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromcresol. Clin Chim Acta. 1971;31:87-96..
18. Flodin M, Hasson LO ,Larsson A. Variations in assay protocol for the Dako cystatin c method may change results by 50% with changing the result control .Clin Chem Lab Med 2006;44: 1482-1485.
19. Go AS, Chertow GM, Fan D, McCulloch CE, et al. Chronic kidney disease and the risk of death cardiovascular events, and hospitalization. N Engl J Med. 2004;531:1296-1305.
20. Vanholder R, Massy Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and morbidity. Nephrol Dial Trans. 2005;20:1048-1056.
21. Qing X, Furong W, Yunxia L, Jian Z, Xuping W, Ling G. Cystatin C and asymptomatic coronary artery disease in patients with metabolic syndrome and normal glomerular filtration rate. Cardiovasc Diabetol. 2012;11:108. doi: 10.1186/1475-2840-11-108.
22. Trilki S, Fekih O, Hellara I, et al. Association between serum Cystatin C levels and cardiovascular disease in type 2 diabetes patients. Ann Bio Clin. 2013;71(4):438-442.
23. Andrzej S, Krolewski, James H et al. Serum concentration of Cystatin C and risk of end–stage renal disease in diabetes. Diabetes Care. 2013;35:2311-2316.
24. Ristiniemi N, Savage C, Bruun L et al. Evaluation of a new immunoassay for Cystatin C , based on a double monoclonal principle , in men with normal and impaired renal function. Nephrol Dial. 1-6:0:2011.
25. Parikh NI, Hwang SJ, Yang Q, et al. Clinical correlates and heritability of cystatin C (from the Framingham Offspring Study). Am J Cardiol. 2008;102:1194–1198.
26. Massy ZA, de Zeeuw D. LDL cholesterol in CKD to treat or not to treat? Kidney Int. 2013;84(3):451-456.
27. Font R, Prats M, Gutiérrez C, et al. Is there a relationship between cystatin C and inflammatory status, oxidative stress and other cardiovascular risk factors in non-diabetic patients with chronic kidney disease? Nefrologia. 2009;29(3):228-235.
28. Sharma S, Ranjan R, Gupta M, et al. Serum Cystatin C compared with conventional renal function tests: A study in patients with pre-eclampsia. Annals of Pathology and Laboratory Medicine, 2014:1(2); A6-A9.
29. Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–2116.
Original Article